Literatura ACTA MEDICINAE 8/2019 Pneumologie

Literatura 3 Screening plicní rakoviny už se nemůžeme vymlouvat MUDr. Jiří Votruba, Ph.D. I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha doc. MUDr. Ing. Lukáš Lambert, Ph.D. Radiodiagnostická klinika VFN a 1. LF UK, Praha prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 3 Novinky v imunoterapii karcinomu plic prof. MUDr. Jana Skřičková, CSc. MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a TBC LF MU a FN Brno 3 Lorlatinib zařazení do aktuální léčebné praxe prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie, FN a LF UK Plzeň 3 Imunoterapie v první linii léčby metastatického nemalobuněčného plicního karcinomu MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 4 Novinky v léčbě pokročilého karcinomu plic MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a tuberkulózy FN Brno 5 Kauzální léčba cystické fibrózy MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Praha 5 Současnost a novinky v léčbě idiopatické plicní fibrózy MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice a Interní ambulance Nemocnice Na Homolce, Praha 5 Antifibrotická léčba u idiopatické plicní fibrózy kazuistika MUDr. Jan Anton prof. MUDr. Martina Vašáková, Ph.D. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerova nemocnice, Praha 5 Fixní inhalační trojkombinace v léčbě chronické obstrukční plicní nemoci doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha 5 Jak motivovat pacienty s CHOPN k dostatečné pohybové aktivitě doc. Mgr. Kateřina Neumannová, Ph.D. Katedra fyzioterapie, Fakulta tělesné kultury, Univerzita Palackého v Olomouci 6 Možnosti psychoterapie pacientů s chronickou obstrukční plicní nemocí doc. PhDr. Dr. phil. Laura Janáčková, CSc. Sexuologický ústav VFN a 1. LF UK Praha 6 CHOPN na podkladě deficitu α 1 antitrypsinu, poznatky z národního registru MUDr. Jan Chlumský, Ph.D. Pneumologická klinika, 1. LF UK a FTN, Praha Mgr. Markéta Škrobáčková Institut biostatiky a analýz, s. r. o., Brno 6 Relvar v běžné klinické praxi MUDr. Iva Pončáková doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha 6 Očkování proti pneumokokům, rizikové skupiny doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha 6 Eozinofil MUDr. Mojmír Račanský doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN Olomouc 7 Současný pohled na léčbu astmatu u dětí prof. MUDr. Petr Pohunek, CSc. Pediatrická klinika 2. LF UK a FN v Motole, Praha 7 Novinky v terapii astmatu dle GINA 2019 MUDr. Ester Seberová Poliklinika Husova, Plzeň 7 Aplikace Těžké astma nová pomůcka pro lékaře i pacienty MUDr. Vratislav Sedlák, Ph.D. Plicní klinika LF UK, FN Hradec Králové MUDr. Irena Krčmová, CSc. Ústav klinické imunologie a alergologie LF UK, FN Hradec Králové MUDr. Olga Růžičková Klinika plicních nemocí a TBC LF UK, FN Plzeň Ing. Jakub Kohout Encode Solutions, s. r. o., Hradec Králové

7 Endotypově specifická léčba omalizumabem MUDr. Jakub Novosad, Ph.D. MUDr. Irena Krčmová, CSc. Ústav klinické imunologie a alergologie, FN Hradec Králové, LF v Hradci Králové, UK v Praze 8 Sarkoidóza současná léčebná strategie prof. MUDr. Vítězslav Kolek, DrSc. MUDr. Monika Žurková MUDr. Vladimíra Lošťáková Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc 8 Nová směrnice WHO léčby multirezistentní tuberkulózy MUDr. Jiří Wallenfels Národní jednotka dohledu nad tuberkulózou, Nemocnice Na Bulovce, Praha 9 Usnadnění expektorace pomocí přístroje CoughAssist doc. Mgr. Kateřina Neumannová, Ph.D. Mgr. Tamara Michalčíková Katedra fyzioterapie, Fakulta tělesné kultury UP v Olomouci 9 Trénink nádechových svalů v klinické praxi Mgr. Petra Žurková, Ph.D. Kardioplicní rehabilitace, s. r. o., Ostrava

Screening plicní rakoviny už se nemůžeme vymlouvat MUDr. Jiří Votruba, Ph.D. I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha doc. MUDr. Ing. Lukáš Lambert, Ph.D. Radiodiagnostická klinika VFN a 1. LF UK, Praha prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Humphrey, L. L. Deffebach, M.: Screening for lung cancer with lowdose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med, 2013, 159, s. 411 420. 2 Bach, P. B.: Is our natural history model of lung cancer wrong? Lancet Oncol, 2008, 9, s. 693. 3 Bach, P. B.: Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax, 2008, 63, s. 298 300. 4 Wasswa-Kintu, S., et al.: Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax, 2005, 60, s. 570 575, review. 5 Salaün,M., et al.: Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am J Respir Crit Care Med, 2008, 177, s. 880 886. 6 Keane, J., et al.: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med, 2007, 13, s. 361 366. 7 Kurie, J. M. Lee, J. S. Morice, R, C., et al.: Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst, 1998, 90, s. 991 995. 8 Khorana, A. A. Tullio, K. Elson, P., et al.: Time to initial cancer treatment in the United States and association with survival overtime: An observational study. PLoS One, 2019, 14, e0213209. 9 Pham, D. Bhandrai, S., et al.: Lung cancer screening rates: Data from the lung cancer screening registry. 2018 ASCO Annual Meeting. J Clin Oncol, 2018, 36, suppl., abstrakt 6504. 10 De Koning, H. J. Erasmus, M. C.: Přednáška na International Association for the Study of Lung Cancer s (IASLC s) 19 th World Conference on Lung Cancer (WSLC), Toronto, Kanada. 25. 9. 2108. 11 Oudkerk, M. Devaraj, A. Vliegenthart, R., et al.: European position statement on lung cancer screening. Lancet Oncol, 2017, 18, s. e754 e766. 12 Dostupné z: https://www.acr.org/-/media/acr/files/practice-parameters/ct-lungcascr.pdf, vyhledáno 21. 3. 2019. Novinky v imunoterapii karcinomu plic prof. MUDr. Jana Skřičková, CSc. MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a TBC LF MU a FN Brno 1 Howlader, N.., et al.:, editors: SEER Cancer Statistics Review, 1975 2008. Bethesda (MD): National Cancer Institute; 2010. Dostupné z: http://seer.cancer.gov/csr/1975_2008/, vyhledáno 23. 4. 2019. 2 www.svod.cz 3 Skřičková, J. Kadlec, B. Venclíček, O.: Nemalobuněčný karcinom plic. Vnitřní lékařství, 2017, 63, 11. 4 Koubková, L.: Imunoterapie karcinomu plic. Postrgraduální medicína, 2015, 17, příloha 1, s. 51 54. 5 Socinski, M. Creelan, B. Horn, L.., et al.: NSCLC, metastatic Check- Mate 026: a phase 3 trial of nivolumab vs investigator s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/ recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol, 2016, 27. 6 Borghaei, H. Hellman, M. D. Paz-Ares, L. G., et al.: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as firstline (1L) treatment (Tx) for advanced non-small cell lung cancer (NS- CLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. J Clin Oncol, 2018, 36, suppl., abstrakt 9001. 7 Hellmann, M. D. Ciuleanu, T. E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s. 2093 2104. 8 Herbst, R. S. Baas, P. Kim, D. W., et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-smallcell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 2016, 387, s. 1540 1550. 9 Brahmer, J. R. Rodriguez-Abreu, D. Robinson, A. G., et al.: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE-024. J Clin Oncol, 2017, 35, suppl., abstrakt 9000. 10 Roach, C. Zhang, N. Corigliano, E., et al.: Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol, 2016, 24, s. 392 397. 11 Reck, M. Rodríguez-Abreu, D. Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375, s. 1823 1833. 12 Lopes, G. Wu, Y.-L. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol, 2018, 36, suppl., abstrakt LBA4. 13 Langer, C. J. Gadgeel, S. M. Borghaei, H., et al.: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol, 2016, 17, s. 1497 1508. 14 Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018, 378, s. 2078 2092. 15 Paz-Ares, L. Luft, A. Vicente, D., et al.: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med, 2018, 379, s. 2040 2051. 16 Socinski, M. A. Jotte, R. M. Cappuzzo, F., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s. 2288 2301. 17 Jotte, R. M. Cappuzzo, F. Vynnychenko, I., et al.: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt LBA9000. 18 Socinski, M. A. Jotte, R. M. Cappuzzo, F., et al.: Overall survival (OS) analysis of IMpower150, a randomized Phase 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt 9002. 19 Horn, L., et al.: First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med, 2018, 379, s. 2220 2229. 20 Antonia, S. J., et al.: Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med, 2017, 377, s. 1919 1929. 21 Antonia, S. J., et al.: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. Article and Supplementary Appendix; N Eng J Med, 2018, 379, s. 2342 2350. 22 Data FDA-U.S. Food and Drug Administration. FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing. Dostupné z: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm597217.htm, vyhledáno 20. 2. 2019. 23 Spigel, D. McLeod, M. Hussein, M., et al.: Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). ESMO 2017, 12970. 24 Herbst, R. S. Garon, E. B. Kim, D., et al.: LBA63 Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro). Ann Oncol, 2018, 29S, 8. Lorlatinib zařazení do aktuální léčebné praxe prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie, FN a LF UK Plzeň 1 Pešek, M., et al.: Správné postupy v léčbě ALK a ROS1 pozitivních karcinomů plic. Akreditovaný kurz ČLK. 2 Shaw, A. T. Felip, E. Bauer, T. M., et al.: Lorlatinib in non-smallcell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol, 2017, 18, s. 1590 1599. 3 Bauer, T. M. Felip, E. Solomon, B. J., et al.: Clinical management of adverse events associated with lorlatinib. Oncologist, 2019, 24, s. 1 8. 4 Shaw, A. T. Solomon, B. J. Besse, B., et al.: ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol, 2019, 37, s. 1 11. 5 Solomon, B. Besse, B. Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 2018, 19, s. 1654 1667. 6 Soda, M. Choi, Y. L. Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448, s. 561 566. 7 Sasaki, T. Rodig, S. J. Chirieac, L. R., et al.: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 2010, 46, s. 1773 1780. 8 Wu, et al.: Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One, 2013, 8, e70839. 9 Teixidó, C. Karachaliou, N. Peg, V., et al.: Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res, 2014, 3, s. 70 74, doi: 10.3978/j.issn.2218-6751.2014.02.02. 10 Gainor, J. F., et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov, 2016, 6, s. 1118 1133. 11 Toyokawa, G. Seto, T.: Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat, 2015, 38, s. 291 298. 12 Lin, J. J. Riely, G. J. Shaw, A. T.: Targeting ALK: precision medicine takes on drug resistance. Cancer Discov, 2017, 7, s. 137 155. 13 Miyamoto, S. Ikushima, S. Ono, R., et al.: Transformation to smallcell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol, 2016, 46, s. 170 173. 14 Ou, S. H., et al.: prezentace na ASCO 2017. 15 Bergethon, K. Shaw, A. T. Ou, S. H., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30, s. 863 870. 16 Takeuchi, K. Soda, M. Togashi, Y., et al.: RET, ROS1 and ALK fusions in lung cancer. Nat Med, 2012, 18, s. 378 381. Imunoterapie v první linii léčby metastatického nemalobuněčného plicního karcinomu MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 1 Yan, Y. Kumar, A. B. Finnes, H., et al.: Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol, 2018, 9, s. 1739. 2 Lazzari, C. Karachaliou, N. Bulotta, A., et al.: Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol,

2018, 10, 1758835918762094, publikováno online 6. 4. 2018. 3 Reck, M. Rodríguez-Abreu, D. Robinson, A. G., et al.: Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol, 8. 1. 2019, JCO1800149. 4 Brahmer, J. R. Rodriguez-Abreu, D. Robinson, A. G., et al.: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE-024. 2017 ASCO Annual Meeting. J Clin Oncol, 2017, 35, suppl., abstrakt 9000. 5 Lopes, G. Wu, Y. L. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Late breaking abstract presentation at: 2018 ASCO Annual Meeting; 1. 5. 6. 2018; Chicago, IL. 6 Garassino, M. C. Gadgeel, S. Esteban, E., et al.: Outcomes among patients with metastatic non-squamous NSCLC with liver metastasis or brain treated with pembrolizumab plus pemetrexed platinum: results from keynote 189. AACR Annual Meeting 2019; vol. 60. 29. 3. 3. 4. 2018; Georgia World Congress Center, Atlanta, GA. 7 Papadimitrakopoulou, V. Gadgeel, S. M. Borghaei, H., et al.: Firstline carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced non-squamous NSCLC: Updated results of KEYNOTE-021 cohort G. 2017 ASCO Annual Meeting. Poster Session (Board #420). J Clin Oncol, 2017, 35, suppl., abstrakt 9094. 8 Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 16. 4. 2018. 9 Abreu, D. R. Garassino, M. C. Esteban, E., et al.: KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, non-squamous NSCLC: Does choice of platinum affects outcomes? An Oncol, 2018, 29, suppl. 8, viii493-viii547, 10.1093/annonc/mdy292. 10 Gadgeel, S. M. Garassino, M. C. Esteban, E., et al.: KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J Clin Oncol, 2019, 37, suppl., abstrakt 9013. 11 Mok, T. S. K. Wu, Y.-L. Kudaba, I., et al.: Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1 positive locally advanced/metastatic NSCLC. An Oncol, 30, suppl. 2, duben 2019, mdz063. 12 Reck, M., et al.: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IM- POWER150). An Oncol, 2017, 28, suppl. 11, mdx760.002. 13 Socinski, M. A., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s. 2288 2301. 14 Socinski, M. A. Rittmeyer, D. Shapovalov, D., et al.: IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel. An Oncol, 2018, 29, suppl. 8, říjen 2018. 15 Paz-Ares, L. Luft, A. Vicente, D., et al.: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med, 2018, 379, s. 2040 2051. 16 Halmos, B. Luft, A. Majem, M., et al.: Choice of taxane and outcomes in the KEYNOTE-407 study of pembrolizumab plus chemotherapy for metastatic squamous NSCLC. Abstrakt MA10.08. IASLC 19 th World Conference on Lung Cancer 2018. 17 Jotte, R. M., et al.: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol, 2018, 36, suppl., abstr LBA9000. 18 Borghaei, H. Hellmann, M. D. Paz-Ares, L. G., et al.: Nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy in chemo-naive patients with advanced non-small cell lung cancer and <1% tumor PD-L1 expression: results from CheckMate 227. J Clin Oncol, 2018, 36, suppl., s. 9001 9001. 19 Hellmann, M. D. Ciuleanu, T. E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s. 2093 2104. 20 Reinmuth, N. Cho, B. Lee, K., et al.: Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. Prezentováno na European Lung Cancer Congress; 11. 13. 4. 2019, Ženeva, Švýcarsko, abstrakt LBA4. 21 Zhou, Y. Lin, Z. Zhang, X., et al.: First-line treatment for patients with advanced non-small-cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer, 2019, 7, s. 120. Novinky v léčbě pokročilého karcinomu plic MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a tuberkulózy FN Brno 1 Skřičková, J. Kadlec, B. Venclíček, O.: Nemalobuněčný karcinom plic. Vnitř Lék, 2017, 63, s. 861 874 2 Skřičková, J. Babičková, L. Tomísková, M. Kadlec, B.: Biologická léčba nemalobuněčného karcinomu plic. Interní Med, 2011, 13, s. 7 8. 3 Lynch, T. J. Bell, D. W. Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor under lying responsive ness of non-small-cell lung cancer to gefitinib. N Engl J. Med, 2004, 350, s. 2129 2139. 4 Meador, C. B. Jin, H. de Stanchina, E., et al.: Optimizing the sequence of anti-egfr-targeted therapy in EGFR-mutant lung cancer. Mol Cancer Ther, 2015, 14, s. 542 552. 5 Soejima, K. Yasuda, H. Hirano, T.: Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Rev Clin Pharmacol, 2017, 10, s. 31 38. 6 Socinski, M. A. Villaruz, L. C. Ross, J.: Under standing mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsyat progression. Oncologist, 2017, 22, s. 3 11. 7 Mok, T. S. Wu, Y. L. Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376, s. 629 640. 8 Cross, D. A. Ashton, S. E. Ghiorghiu, S., et al.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov, 2014, 4, s. 1046 1061. 9 Zhang, H.: Osimertinib making a break through in lung cancer targeted therapy. Onco Targets Therm, 2016, 9, s. 5489 5493. 10 Zugazagoitia, J. Ferrer, I. Paz-Ares, L.: Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. Lancet Oncol, 2016, 17, s. 1622 1623. 11 Greig, S. L.: Osimertinib: first global approval. Drugs, 2016, 76, s. 263 273. 12 Paz-Ares, L. de Marinis, F. Dediu, M., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARA- MOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol, 2012, 13, s. 247 255. 13 Ramalingam, S. Yang, J. C. Lee, C. K., et al.: Osimertinib as firstline treatment for EGFR mutation-positive advanced NSCLC: update defficacy and safety results from two phase I expansion cohorts. Prezentováno na European Lung Cancer Conference, 13. 16. 4. 2016; Ženeva, Švýcarsko, abstrakt LBA 1. 14 Yang, J. C. Ramalingam, S. Jänne, P. A., et al.: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated phase 1 (p1) and pooled phase 2 (p2) results. Prezentováno na European Lung Cancer Conference, 13. 16. 4. 2016; Ženeva, Švýcarsko, abstrakt LBA 2. 15 Ho, C. C. Liao, W. Y. Lin, C. A., et al.: Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol, 2017, 12, s. 567 572. 16 Ou, S. H. Agarwal, N. Ali, S. M.: High MET amplification level as a resistence mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer, 2016, 98, s. 59 61. 17 Ortiz-Cuaran, S. Scheffler, M. Plenker, D., et al.: Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res, 2016, 22, s. 4837 4847. 18 Wang, S. Song, Y. Yan, F. Liu, D.: Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med, 2016, 10, s. 383 388. 19 Steuer, C. E. Khuri, F. R. Ramalingam, S. S., et al.: The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer, 2015, 121, s. E1 E6. 20 Thress, K. S. Paweletz, C. P. Felip, E., et al.: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med, 2015, 21, s. 560 562. 21 Soda, M. Choi, Y. L. Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, s. 561 566. 22 Gainor, J. F. Varghese, A. M. Ou, S. H., et al.: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res, 2013, 19, s. 4273 4281. 23 Shaw, A. T. Yeap, B. Y. Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27, s. 4247 4253. 24 Choi, Y. L. Soda, M. Yamashita, Y., et al.; ALK Lung Cancer Study Group: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 2010, 363, s. 1734 1739. 25 Camidge, D. R. Bang, Y. J. Kwak, E. L., et al.: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 2012, 13, s. 1011 1019. 26 Doebele, R. C. Pilling, A. B. Aisner, D. L., et al.: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res, 2012, 18, s. 1472 1482. 27 Sasaki, T. Koivunen, J. Ogino, A., et al.: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res, 2011, 71, s. 6051 6060. 28 Mok, T., et al.: ASCEND-2: a single-arm, open-label, multicenter Phase 2 study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Annual Meeting, J Clin Oncol, 2015, 33, suppl., s. 8059 8059. 29 Peters, S., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017, 377, s. 829 838. 30 Raez, L. E. Fein, S. Podack, E. R.: Lung cancer immunotherapy. Clin Med Res, 2005, 3, s. 221 228. 31 Reck, M. Rodríguez-Abreu, D. Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non small-cell lung cancer. N Engl J Med, 2016, 375, s. 1823 1833. 32 Pardoll, D. M.: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12, s. 252 264. 33 Paz-Ares, L. G. Luft, A. Tafreshi, A., et al.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol, 2018, 36, suppl., abstrakt 105. 34 Fehrenbacher, L. Spira, A. Ballinger, M., et al.: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387, s. 1837 1846. 35 Rittmeyer, A. Barlesi, F. Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389, s. 255 265. 36 Peters, S. Gettinger, S. Johnson, M. L., et al.: Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1 selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol, 2017, 35, s. 2781 2789. 37 Phase III IMpower150 Study Showed Genentech s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel. Dostupné z: https://www.roche.com/investors/updates/inv-update-2018-03-26. htm, vyhledáno 7. 3. 2019. 38 Garassino, M. Paz-Ares Rodriges, L., et al.: Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLAN- TIC): an open-label, single-arm, phase 2 study. Lancet Oncol, 2018, 19, s. 521 536. 39 Antonia S. Villegas, A. Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non small-cell lung cancer. N Engl J Med, 2017, 377, s. 1919 1929. 40 Ryška, A., et al.: Testování PD-L1 nová výzva v prediktivní diagnostice nemalobuněčných plicních karcinomů, Acta Medicinae, 2016, 8, s. 37 40. 41 Dung T. Le, et al.: Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, s. 409 413. 42 Ryška, A.: Kdo bude profitovat z imunoterapie. Terapie, 2018, 6. Dostupné z: http://terapie.digital/kongresy/kongresy-domaci, vyhledáno 7. 3. 2019. 43 Rimm, D. L.: In discussion of: Tumor Mutational Burden (TMB) as a Biomarker for Clinical Benefit from Dual Immune Checkpoint Blockade With Nivolumab + Ipilimumab in First-Line Non-Small Cell Lung Cancer: Identification of TMB Cut off From CheckMate 568. Pezentováno na American Association for Cancer Research Annual Meeting, 14. 18. 4. 2018, Chicago, IL 44 Green, S., et al.: Immune signatures of non-small cell lung cancer. J Thoracic Oncol, 2017,12, s. 913 915.

Kauzální léčba cystické fibrózy MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Praha 1 Alton, E. W. F. W. Armstrong, D. K. Ashby, D., et al.; UK Cystic Fibrosis Gene Therapy Consortium: Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med, 2015, 3, s. 684 691. 2 Clancy, J. P. Cotton, C. U. Donaldson, S. H., et al.: CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros, 2019, 18, s. 22 34. 3 Cooney, A. L. McCray, P. B. Jr. Sinn, P. L.: Cystic fibrosis gene therapy: looking back, looking forward. Genes (Basel), 2018, 9. 4 Davies, J. C. Wainwright, C. E. Canny, G. J., et al.; VX08-770-103 (ENVISION) Study Group: Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med, 2013, 187, s. 1219 1225. 5 Guimbellot, J. Sharma, J. Rowe, S. M.: Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol, 2017, 52, s. S4 S14. 6 Marangi, M. Pistritto, G.: Innovative therapeutic strategies for cystic fibrosis: moving forward to CRISPR technique. Front Pharmacol, 2018, 9, s. 396. 7 Marson, F. A. L. Bertuzzo, C. S. Ribeiro, J. D.: Personalized or precision medicine? The example of cystic fibrosis. Front Pharmacol, 2017, 8, s. 390. 8 Noordhoek, J. Gulmans, V. van der Ent, K., et al.: Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration. Curr Opin Pulm Med, 2016, 22, s. 610 616. 9 Ramsey, B. W. Davies, J. McElvaney, N. G., et al.; VX08-770-102 Study Group: A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med, 2011, 365, s. 1663 1672. 10 Rowe, S. M. Daines, C. Ringshausen, F. C., et al.: Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med, 2017, 377, s. 2024 2035. 11 Taylor-Cousar, J. L. Munck, A. McKone, E. F., et al.: Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med, 2017, 377, s. 2013 2023. 12 Wainwright, C. E. Elborn, J. S. Ramsey, B. W., et al.; TRAFFIC Study Group; TRANSPORT Study Group: Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med, 2015, 373, s. 220 231. 13 Dostupné z: www.cff.org/trials/pipeline, vyhledáno 1. 3. 2019. 14 Dostupné z: www.ema.europa.eu/documents/product-information/ kalydeco-epar-product-information_cs.pdf, vyhledáno 1. 3. 2019. 15 Dostupné z: www.ema.europa.eu/documents/product-information/ orkambi-epar-product-information_cs.pdf, vyhledáno 1. 3. 2019. 16 Dostupné z: www.ema.europa.eu/documents/product-information/ symkevi-epar-product-information_cs.pdf, vyhledáno 1. 3. 2019. 17 Dostupné z: www.hitcf.org, vyhledáno 1. 3. 2019. 18 Dostupné z: www.sukl.cz/modules/medication/detail. php?code=0185303&tab=prices, vyhledáno 1. 3. 2019. Současnost a novinky v léčbě idiopatické plicní fibrózy MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice a Interní ambulance Nemocnice Na Homolce, Praha 1 Raghu, G. Remy-Jardin, M. Myers, J. L., et al.; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society: Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2018, 198, s. e44 e68. 2 Oldham, J. M. Ma, S. F. Martinez, F. J., et al.; IPFnet Investigators: TOLLIP, MUC5B, and the response to N-Acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2015, 192, s. 1475 1482. 3 Oldham, J. M. Witt, L. J. Adegunsoye, A., et al.: N-acetylcysteine exposureis associated with improved survival in anti-nuclear antipody seropositive patients with usual interstitial pneumonia. BMC Pulm Med, 2018, 18, s. 30. 4 Torrisi, S. E. Vancheri, A. Pavone, M., et al.: Comorbidities of IPF: How do Theky impact on prognosis. Pulm Pharmacol Ther, 2018, 53, s. 6 11. 5 Kreuter, M. Wijsenbeek, M. S. Vasakova, M., et al.: Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J, 2016, 47, s. 1776 1784. 6 Kreuter, M. Bonella, F. Maher, T. M., et al.: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, s. 148 153. 7 Shah, R. R. Morganroth, J.: Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf, 2015, 38, s. 693 710. 8 Crestani, B. Huggins, J. T. Kaye, M., et al.: Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med, 2019, 7, s. 60 68. 9 Fisher, M. Nathan, S. D. Hill, C., et al.: Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm, 2017, 23, suppl. 3-b, s. S17 S24. 10 Perez-Bogerd, S. Wuyts, W. Barbier, V., et al.: Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res, 2018, 19, s. 182. 11 Cheng, L. Tan, B. Yin, Y., et al.: Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil, 2018, 32, s. 1299 1307. 12 Bell, E. C. Cox, N. S. Goh, N., et al.: Oxygen therapy for interstitial lung disease: a systematic review. Eur Resp Rev, 2017, 26, s. 160080. 13 Noble, P. W. Albera, C. Bradford, W. Z., et al.: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011, 377, s. 1760 1769. 14 King, T. E. Jr. Bradford, W. Z. Castro-Bernardini, S., et al.: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370, s. 2083 2092. Antifibrotická léčba u idiopatické plicní fibrózy kazuistika MUDr. Jan Anton prof. MUDr. Martina Vašáková, Ph.D. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerova nemocnice, Praha 1 Raghu, G. Collard, H. R. Egan, J. J.: American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. AJRCCM, 2000, 161, s. 646 664. 2 Lynch, III. J. P. Wurfel, M. Flaherty, K., et al.: Usual interstitial pneumonia. Semin Respir Crit Care Med, 2001, 22, s. 357 385. 3 Raghu, G. Lynch, III. J. P. Wurfel, M. Flaherty, K., et al.: Usual interstitial pneumonia. Semin Respir Crit Care Med, 2001, 22, s. 357 385. 4 Remy-Jardin, M. Lynch, III. J. P. Wurfel, M. Flaherty, K., et al.: Usual interstitial pneumonia. Semin Respir Crit Care Med, 2001, 22, s. 357 385. 5 Myers, J. L., et al.: Diagnosis of idiopathic pulmonary fibrosis an official ATS/ERS/JRS/ALAT clinical practice guideline: executive summary. Am J Respir Crit Care Med, 2018, 198, s. 563 580. Fixní inhalační trojkombinace v léčbě chronické obstrukční plicní nemoci doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha 1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. 2017. Dostupné z: www.goldcopd.org. 2 Vestbo, J. Papi, A. Corradi, M., et al.: Single inhalare extrafine triple therapy versus long-acting muscarinic antagonost therapy for chronic obstructive pulmonary disease (TRINITY); a double-blind, parallel group, randomised controlled trial. Lancet, 2017, 389, s. 1919 1929. 3 Švarc, M.: Postavení inhalačních kortikosteroidů v terapii chronické obstrukční plicní nemoci. Acta medicinae, 2018, 8, s. 3 5. 4 Pavord, I. D. Lettis, S. Locantore, N., et al.: Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax, 2016, 71, s. 118 125. 5 Singh, D. Papi, A. Corradi, M., et al.: Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β 2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet, 2016, 388, s. 963 973. 6 Papi, A. Vestbo, J. Fabbri, L, et al.: Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trual. Lancet, 2018, 391, s. 1076 1084. 7 Singh, D. Corradi, M. Spinola, M., et al.: Triple therapy in COPD: new evidence with the exrtafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J of COPD, 2017, 12, s. 2917 2928. Jak motivovat pacienty s CHOPN k dostatečné pohybové aktivitě doc. Mgr. Kateřina Neumannová, Ph.D. Katedra fyzioterapie, Fakulta tělesné kultury, Univerzita Palackého v Olomouci 1 Biswas, A. Oh, P. I. Faulkner, G. E., et al.: Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults a systematic review and meta-analysissed entery time and disease incidence, mortality, and hospitalization. An Intern Med, 2015, 162, s. 123 132. 2 Commission of the European communities (2007). White paper on a strategy for Europe on nutrition, overweight and obesity related health issues. Dostupné z: http://ec.europa.eu/health/archive/ph_ determinants/life_style/nutrition/documents/nutrition_wp_en.pdf, vyhledáno 25. 2. 2019. 3 Tremblay, M. S. Colley, R. C. Saunders, T. J., et al.: Physiological and health implications of a sedentary life style. Ap Physiol Nutr Metab, 2010, 35, s. 725 740. 4 Ding, D. Lawson, K. D. Kolbe-Alexander, T. L., et al.; Lancet Physical Activity Series 2 Executive Committee: The economic burden of physicalin activity: a global analysis of major non-communicable diseases. Lancet, 2016, 388, s. 1311 1324. 5 Durstine, J. L. Gordon, B. Wang, Z., et al.: Chronic disease and the

link to physical activity. J Sport Health Science, 2013, 2, s. 3 11. 6 Waschki, B. Kirsten, A. Holz, O., et al.: Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest, 2011, 140, s. 331 342. 7 Vaes, A. W. Garcia-Aymerich, J. Marott, J. L., et al.: Changes in physical activity and all-cause mortality in COPD. Eur Resp J, 2014, 44, s. 1199 1209. 8 Benzo, R. P. Chang, C. C. H. Farrell, M. H., et al. & NETT Research Group: Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration, 2010, 80, s. 10 18. 9 Global Iniative for Chronic Obstructive Lung Disease (2019). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Dostupné z: https://goldcopd.org/ wp-content/uploads/2018/11/gold-2019-v1.7-final-14nov2018- WMS.pdf, vyhledáno 25. 2. 2019. 10 Pitta, F. Troosters, T. Spruit, M. A., et al.: Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Resp Crit Care Med, 2005, 171, s. 972 977. 11 Vorrink, S. N. Kort, H. S. Troosters, T., et al.: Level of daily physical activity in individuals with COPD compared with healthy controls. Resp Res, 2011, 12, s. 33. 12 Watz, H. Waschki, B. Meyer, T., et al.: Physical activity in patients with COPD. Eur Resp J, 2009, 33, s. 262 272. 13 Troosters, T. van der Molen, T. Polkey, M., et al.: Improving physical activity in COPD: towards a new paradigm. Resp Res, 2013, 14, s. 115. 14 Jones, P. W. Brusselle, G. Dal Negro, R. W., et al.: Health-related quality of life in patients by COPD severity within primary care in Europe. Resp Med, 2011, 105, s. 57 66. 15 Rodó-Pin, A. Balañá, A. Molina, L., et al.: Level of daily physical activity in chronic obstructive pulmonary disease (COPD) patients according to GOLD classification. Medicina Clínica, 2017, 148, s. 114 117. 16 Troosters, T. Sciurba, F. Battaglia, S., et al.: Physical in activity in patients with COPD, a controlled multi-center pilot-study. Resp Med, 2011, 104, s. 1005 1011. 17 Shrikrishna, D. Patel, M. Tanner, R. J., et al.: Quadriceps wasting and physical in activity in patients with COPD. Eur Resp J, 2012, 40, s. 1115 1122. 18 Van Remoortel, H. Hornikx, M. Demeyer, H., et al.: Daily physical activity in subjects with newly diagnosed COPD. Thorax, 2013, 68, s. 962 963. 19 Neumannová, K. Janura, M. Kováčiková, Z., et al.: Analýza chůze u nemocných s chronickou obstrukční plicní nemocí. Olomouc, Univerzita Palackého, 2015. 20 Watz, H. Pitta, F. Rochester, C. L., et al.: An official European Respiratory Society statement on physical activity in COPD. Eur Resp J, 2014, 4, s. 1521 1537. 21 Neumannová, K.: Vliv rehabilitační léčby na úroveň pohybových aktivit u nemocných s chronickou obstrukční plicní nemocí. Studia Pneumologica et Phthiseologica, 2017, 77, s. 14 18. 22 Van Buul, A. R. Kasteleyn, M. J. Chavannes, N. H., et al.: Association between mening symptoms and physical activity in COPD: a systematic review. Eur Resp Rev, 2017, 26, s. 1 12. 23 Neumannová, K. Kolek, V. Zatloukal, J., et al.: Asthma bronchiale a chronická obstrukční plicní nemoc možnosti komplexní léčby z pohledu fyzioterapeuta. Praha, Mladá fronta, 2018. 24 Neumannová, K. Zatloukal, J. Koblížek, V.: Doporučený postup pro plicní rehabilitaci. ČPFS ČLS JEP, sekce nemocí s bronchiální obstrukcí. 2014, dostupné z: www.pneumologie.cz/upload/1406799894. pdf, vyhledáno 25. 2. 2019. Možnosti psychoterapie pacientů s chronickou obstrukční plicní nemocí doc. PhDr. Dr. phil. Laura Janáčková, CSc. Sexuologický ústav VFN a 1. LF UK Praha 1 Ciaramicoli, A. P. Ketcham, K.: Der Empathie Faktor. Mitgefühl, Toleranz, Verstandnis. Taschenbuch, Mnichov, 2001. 2 Janáčková, L.: CHOPN. Jak rozdýchat plicní onemocnění. Mladá fronta, Praha, 2018. 3 Kratochvíl, S.: Základy psychoterapie. Portál, Praha, 2002. 4 Spitzer, K. A. Stefan, M. S. Priya, A., et al.: Participation in pulmonary rehabilitation after hospitalization for chronic obstructive pulmonary disease among medicare beneficiaries. Ann Am Thorac Soc, 2019. CHOPN na podkladě deficitu α 1 antitrypsinu, poznatky z národního registru MUDr. Jan Chlumský, Ph.D. Pneumologická klinika, 1. LF UK a FTN, Praha Mgr. Markéta Škrobáčková Institut biostatiky a analýz, s. r. o., Brno 1 Stoller, J. K. Aboussouan, L. S.: A review of α-1-antitrypsin deficiency. Am J Respir Crit Care Med, 2012, 185, s. 246 259. 2 Stoller, J. K.: American Thoracic Society/European Respiratory Society Statement. Am J Respir Crit Care Med, 2003, 168, s. 818 900. 3 Kelly, E. Greene, C. M. Carroll, T. P., et al.: Alpha-1 antitrypsin deficiency. Respir Med, 2010, 104, s. 763 772. 4 Campos, M. A. Lascano, J.: Current best practice in testing and augmentation therapy. Ther Adv Resp Dis, 2014, 8, s. 150 161. 5 Vreim, C. E.: Survival and FEV 1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med, 1998, 158, s. 49 59. 6 Stockley, R. A. Parr, D. G. Piitulainen, E., et al.: Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res, 2010, 11, s. 136. 7 Chapman, K. R. Burdon, J. G. W. Piitulainen, E., et al.: Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet, 2015, 386, s. 360 368. Relvar v běžné klinické praxi MUDr. Iva Pončáková doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha 1 Diagnosis of diseases of chronic airflow limitation: Asthma, COPD and Asthma COPD Overlap Syndrome (ACOS). GINA 2014, GOLD 2014. Dostupné z: www.ginaasthma.org, vyhledáno 24. 5. 2019. 2 Global strategy for asthma management and preventiv. Revised 2014. GINA 2014. Dostupné z: www.ginaasthma.org, vyhledáno 24. 5. 2019. 3 Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary dinase. GOLD Report, revised 2015. Dostupné z: www.goldcopd.org, vyhledáno 24. 5. 2019. 4 Koblížek, V. Chlumský, J. Zindr, V., et al.: CHOPN. Doporučený postup ČPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci. Praha, Maxdorf Jessenius, 2013. 5 Zdraví plic Evropě fakta a čísla. ERS, ELF, 2013, ČARO, 2014. 6 Teřl, M. Čáp, P. Dvořáková, R., et al.: Doporučený postup diagnostiky a léčby bronchiálního astmatu. ČPFS, ČSAKI, GEUM, 2015. 7 MacNee, W. Rabinowich, R. Choudhury, G.: Ageing and border between health and dinase. Eur Respir J, 2014, 44, s. 1332 1352. 8 Allen, A. Bareille, P. J. Rousell, V. M.: Fluticasone furoate, a novel inhaled corticosteroid, demonstrated prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet, 2013, 52, s. 37 42. 9 Kašáková, E. Kašák, V.: Inhalační systémy na českém trhu pro léčbu pacientů s chronickou obstrukcí průdušek. Praktické lékárenství, 2015, 11, s. 16 18. 10 Svedsater, H., et al.: Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med, 2018, 141, s. 198 206. Očkování proti pneumokokům, rizikové skupiny doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha 1 Kolek, V.: Infekční pneumonie. In: Kolek, V. Kašák, V., et al.: Pneumologie. Maxdorf Jessenius, 2014, s. 121 143. 2 Froes, F. Diniz, A. Mesquita, M., et al.: Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009. Eur Respir J, 2013, 41, s. 1141 1146. 3 Petroušová, L. Rožnovský, L.: Pneumokokové infekce u dospělých a jejich prevence. Med Praxi, 2013, 10, s. 104 107. 4 Bonten, M. J. Huijts, S. M. Bolkenbass, M., et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med, 2015, 372, s. 1114 1125. 5 Pittet, L. F. Posfay-Barbe, K. M.: Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect, 2012, 18, s. 25 36. 6 Rumlarová, Š.: Kde mohlo pomoci očkování Med Praxi, 2014, 11, s. 182 183. 7 Dostupné z: https://www.prevenar.cz, vyhlednáno 11. 6. 2019. Eozinofil MUDr. Mojmír Račanský doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN Olomouc 1 Kopřiva, F.: Chronický eozinofilní zánět a asthma bronchiale. Praha, Maxdorf, 2003. 2 Weller, P. F., et al.: Eosinophil biology and causes of eosinophilia. Dostupné online z: www.uptodate.com. 3 2018 GINA report, Global Strategy for Asthma Management and Prevention, 2018, www.ginasthma.org. 4 Darveaux, J. Busse, W. W.: Biologics in asthma the next step toward personalized treatment. J Allergy Clin Immunol Pract, 2015, 3, s. 152 160. 5 Stokes, J. R. Casale, T. B.: Characterization of asthma endotypes: implication for therapy. Ann Allergy Asthma Immunol, 2016, 117, s. 121 125. 6 Krings, J. G. Mc Gregor, M. C. Bacharier, L. B., et al.: Biologics for severe asthma: treatment-specific effect are important in choosing a specific agent. J Allergy Clin Immunol Pract, 2019, 7, s. 1379 1392. 7 Bochner, B. S.: The eosinophil For better or worse, in sickness and in health. Ann Allergy Asthma Immunol, 2018, 121, s. 150 155. 8 Krishach, P. A. Louviere, T. J. Decker, T. S., et al.: Protection against Staphylococcus aureus bacteremia-induced mortality depends on ILC2s and eosinophils. GSI insight, 2019, 4, 6.

Současný pohled na léčbu astmatu u dětí prof. MUDr. Petr Pohunek, CSc. Pediatrická klinika 2. LF UK a FN v Motole, Praha 1 Papadopoulos, N. G., et al.: International consensus on (ICON) pediatric asthma. Allergy, 2012, 67, s. 976 997. 2 Global Initiative for Asthma: Asthma Management and Preventionfor Adults and Children older than 5 Years A Pocket Guide for Health Professionals updated 2018. 3 Global Initiative for Asthma: Asthma Management and Prevention for Adults and Children older than 5 Years A Pocket Guide for Health Professionals updated 2019. Dostupné z: https://ginasthma.org/ wp-content/uploads/2019/04/gina-2019-main-pocket-guide-wms. pdf, vyhledáno 20. 5. 2019. 4 Global Initiative for Asthma: Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients updated 2019. Dostupné z: https://ginasthma.org/wp-content/ uploads/2019/04/gina-severe-asthma-pocket-guide-v2.0-wms-1. pdf, vyhledáno 20. 5. 2019. Novinky v terapii astmatu dle GINA 2019 MUDr. Ester Seberová Poliklinika Husova, Plzeň 1 Dusser, D. Montani, D. Chanez, P., et al.: Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy, 2007, 62, s. 591 604. 2 Global Initiative for Asthma. Global strategy for asthma management and prevention. Aktualizováno 2018, www.ginasthma.org, vyhledáno 31. 3. 2109. 3 GINA Report upgrade 2019, http://ginasthma.org/. 4 O Byrne, P. M. FitzGerald, M. Bateman, E. D., et al.: Inhaled combined budesonide plus formoterol as needed in mild asthma [article and supplementary appendix]. N Engl J Med, 2018, 378, s. 1865 1876. 5 Bateman, E. D. Reddel, H. K. O Byrne, P. M., et al.: As-needed budesonide-formoterol versus maintenance budesonide in mild asthma [article and supplementary appendix]. N Engl J Med, 2018, 378, s. 1877 1887. 6 O Byrne, P. M., et al.: The paradoxes of asthma management: time for new approach? Eur Respir J, 2017, 50, s. 1701103. Aplikace Těžké astma nová pomůcka pro lékaře i pacienty MUDr. Vratislav Sedlák, Ph.D. Plicní klinika LF UK, FN Hradec Králové MUDr. Irena Krčmová, CSc. Ústav klinické imunologie a alergologie LF UK, FN Hradec Králové MUDr. Olga Růžičková Klinika plicních nemocí a TBC LF UK, FN Plzeň Ing. Jakub Kohout Encode Solutions, s. r. o., Hradec Králové 1 Kagen, S. Garland, A.: Asthma and allergy mobile apps in 2018. Curr Allergy Asthma Rep, 2019, 19, s. 6. 2 Chan, A. H. Stewart, A. W. Harrison, J., et al.: Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract, 2015, 3, s. 335 349. 3 Teřl, M. Sedlák, V. Čáp, P., et al.: Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. Allergy, 2017, 72, s. 1279 1287. 4 GINA Difficult-to-treat and severe asthma in adolescents and adultpatients. Diagnosis and management. Dostupné z: https://ginasthma. org/wp-content/uploads/2019/04/gina-severe-asthma-pocket- Guide-v2.0-wms-1.pdf, vyhledáno 15. 6. 2019. Endotypově specifická léčba omalizumabem MUDr. Jakub Novosad, Ph.D. MUDr. Irena Krčmová, CSc. Ústav klinické imunologie a alergologie, FN Hradec Králové, LF v Hradci Králové, UK v Praze 1 Teřl, M. Čáp, A. Dvořáková P., et al.: Doporučený postup diagnostiky a léčby bronchiálního astmatu. Geum, 2015. 2 Chung, K. F. Wenzel, S. E. Brozek, J. L., et al.: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma TASK FORCE REPORT ERS/ATS GUIDELINES ON SEVERE ASTHMA Executive Summary. Eur Respir J, 2014, 43, s. 343 373. 3 Hekking, P. P. W. Wener, R. R. Amelink M., et al.: The prevalence of severe refractory asthma. J Allergy Clin Immunol, 2015, 135, s. 896 902. 4 Schleich, F. Brusselle, G. Louis, R., et al.: Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med, 2014, 108, s. 1723 1732. 5 Meltzer, S. J.: Bronchial asthma as a phenomenon of anaphylaxis. J Am Med Assoc, 1910, 55, s. 1021 1024. 6 Rackemann, F. M.: Intrinsic asthma. J Allergy, 1940, 11, s. 147 162. 7 Bennich, H. H. Ishizaka, K. Johansson, S. G. O., et al.: Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ, 1968, 38, s. 151 152. 8 Platts-Mills, T. A. E. Heymann, P. W. Commins, S. P., et al.: The discovery of IgE 50 years later. Ann Allergy Asthma Immunol, 2016, 116, s. 179 182. 9 Stone, K. D. Prussin, C. Metcalfe, D. D.: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol, 2010, 125, s. 73 80. 10 Snapper, C. M. Finkelman, F. D. Paul, W. E.: Regulation of IgG 1 and IgE production by interleukin 4. Immunol Rev, 1988, 102, s. 51 75. 11 Bacharier, L. D. Geha, R. S.: Molecular mechanisms of IgE regulation. J Allergy Clin Immunol, 2000, 105, s. 547 558. 12 Mosmann, T. R. Cherwinski, H. Bond, M. W., et al.: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol, 1986, 136, s. 2348 2357. 13 Loughnan, M. S. Takatsu, K. Harada, N., et al.: T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. Proc Natl Acad Sci U S A, 1987, 84, s. 5399 5403. 14 Takatsu, K. Kikuchi, Y. Takahashi, T., et al.: Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. Proc Natl Acad Sci U S A, 1987, 84, s. 4234 4238. 15 Howard, M. Farrar, J. Hilfiker, M., et al.: Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med, 1982, 155, s. 914 923. 16 Minty, A. Chalon, P. Derocq, J. M., et al.: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature, 1993, 362, s. 248 250. 17 Wills-Karp, M. Luyimbazi, J. Xu, X., et al.: Interleukin-13: central mediator of allergic asthma. Science, 1998, 282, s. 2258 2261. 18 Grünig, G. Warnock, M. Wakil, A. E., et al.: Requirement for IL- 13 independently of IL-4 in experimental asthma. Science, 1998, 282, s. 2261 2263. 19 Goswami, R. Kaplan, M. H.: A brief history of IL-9. J Immunol, 2011, 186, s. 3283 3288. 20 Coffman, R. L. Carty, J. A.: T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol, 1986, 136, s. 949 954. 21 Humbert, M. Durham, S. R. Ying, S., et al.: IL-4 and IL-5 mrna and protein in bronchial biopsies from patients with atopic and nonatopic asthma: Evidence against intrinsic asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med, 1996, 154, s. 1497 1504. 22 Morrow Brown, H. Edin, M. R. C. P. E.: Treatment of chronic asthma with prednisolone. Significance of eosinophils in the sputum. Lancet, 1958, 358, s. 1245 1247. 23 Wenzel, S. E. Schwartz, L. B. Langmack, E. L., et al.: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med, 1999, 160, s. 1001 1008. 24 Harrington, L. E. Hatton, R. D. Mangan, P. R., et al.: Interleukin 17 producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005, 6, s. 1123 1132. 25 Steinman, L.: A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med, 2007, 13, s. 139 145. 26 Cosmi, L. Liotta, F. Annunziato, F.: Th17 regulating lower airway disease. Curr Opin Allergy Clin Immunol, 2016, 16, s. 1 6. 27 Anderson, G. P.: Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet, 2008, 372, s. 1107 1119. 28 Neill, D. R. Wong, S. H. Bellosi, A., et al.: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature, 2010, 464, s. 1367 1370. 29 Kabata, H. Moro, K. Koyasu, S., et al.: Group 2 innate lymphoid cells and asthma. Allergol Int, 2015, 64, s. 227 234. 30 Katial, R. K. K. Bensch, G. W. W. Busse, W. W. W., et al.: Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract, 2017, 5, s. 1 14. 31 Carr, T. F. Zeki, A. A. Kraft, M.: Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med, 2018, 197, s. 22 37. 32 Brusselle, G. Bracke, K.: Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc, 2014, 11, s. 322 328. 33 Vénéreau, E. Ceriotti, C. Bianchi, M. E.: DAMPs from cell death to new life. Front Immunol, 2015, 6, s. 1. 34 Oboki, K. Nakae, S. Matsumoto, K. Saito, H.: IL-33 and airway inflammation. Allergy Asthma Immunol Res, 2011, 3, s. 81 88. 35 Lam, E. P. S. Kariyawasam, H. H. Rana, B. M. J., et al.: IL-25/ IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol, 2016, 137, s. 1514 1524. 36 Dahlén, S.-E.: TSLP in asthma a new kid on the block? N Engl J Med, 2014, 22. 37 Martinon, F. Burns K. Tschopp, J.: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proil-beta. Mol Cell, 2002, 10, s. 417 426. 38 Samitas, K. Zervas, E. Gaga, M.: T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med, 2017, 23, s. 48 55. 39 Robinson, D. Humbert, M. Buhl, R., et al.: Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy, 2017, 47, s. 161 175. 40 FitzGerald, M. Bateman, E. D. Boulet, L.-P., et al.: Global strategy for asthma management and prevention (GINA 2015). 41 Global Initiative For Asthma (GINA). DIFFICULT-TO-TREAT SEVERE ASTHMA in adolescent and adult patients GINA Pocket Guide For Health Professionals Diagnosis and Management, 2019. 42 Marshall, J. S. Bell, E. B.: Induction of an auto-anti-ige response in rats. I. Effects on serum IgE concentrations. Eur J Immunol, 1985, 15, s. 272 277. 43 Corne, J. Djukanovic, R. Thomas, L., et al.: The effect of intravenous administration of a chimeric anti-ige antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J Clin Invest, 1997, 99, s. 879 887. 44 Busse, W. Corren, J. Lanier, B. Q., et al.: Omalizumab, anti-ige recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol, 2001, 108, s. 184 190. 45 Solèr, M. Matz, J. Townley, R., et al.: The anti-ige antibody omalizumab reduces exacerbations and steroid requirement in allergic